Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...

The attempt to add guardrails to Arizona’s high-spending taxpayer-funded school voucher system has cleared one more hurdle.

Objectives Elective non-emergent surgical wait times have increased across countries such as Canada, straining operating room ...